Fig. 4
Solicited reactogenicity during 7 days after Doses 1 and 2 of ARCT-154 or placebo in the phase 3b study, with highest severity indicated as mild (Grade 1), moderate (Grade 2) or severe (Grade 3).
Fig. 4 | Nature Communications
Solicited reactogenicity during 7 days after Doses 1 and 2 of ARCT-154 or placebo in the phase 3b study, with highest severity indicated as mild (Grade 1), moderate (Grade 2) or severe (Grade 3).
